UNSPSC 51121616: Isoxsuprine

This classification denotes a vasodilating agent and beta-adrenergic agonist with the molecular formula C18H23NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R15UI3245N, chemically known as benzyl alcohol, p-hydroxy-alpha-(1-((1-methyl-2-phenoxyethyl)amino)ethyl)- but generally known as isoxsuprine, which bears US NIH Compound Identifier 3783. European Medicines Agency schedules Isoxsuprine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08345MIG.

UNSPSC 51121616 Isoxsuprine, a Commodity code, identifies pharmaceutical products procured by state and local health agencies, emergency services, and cooperative purchasing alliances for clinical and emergency medical use. State and local governments buy specific branded or generic medications under this code to support fire rescue operations, state health programs, pharmacy benefit initiatives, and multistate purchasing cooperatives. The issuing bodies include municipal fire departments, state health and human services commissions, and regional cooperative purchasing organizations serving multiple state and local jurisdictions. Work currently solicited ranges from small-volume emergency medication supplies to large-scale generic pharmaceutical procurement supporting statewide pharmacy networks.

Recent activity spans Florida, Texas, and Minnesota. The City of Tampa's Purchasing Department issued an IFB (Bid No. 26-P-00188) on April 24, 2026, for Advanced Life Support Medications to supply Tampa Fire Rescue with 370 units of Labetalol HCI 100mg vials, 1,810 units of Epinephrine 1:10,000 injections, 330 units of Adenosine 6mg vials, and 1,020 units of Diltiazem 25mg vials, with a response deadline of April 8, 2026, and an estimated contract value of $40,000.00 under a Small Local Business Enterprise sheltered market designation offering a 5 percent bid discount. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP (S1070000015802) due March 26, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities in Minnesota and Oregon, with awarded vendors effective July 1, 2026. The Texas Health and Human Services Commission issued an RFI (HHS0017013) on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program serving self-insured state employee health plans.